BioSpace News Archive

Burning Rock Biotech Limited announced that all shareholder resolutions proposed at the Company’s 2022 annual general meeting held today were duly passed.

Cardior Pharmaceuticals announced the CE marking of its PCR kit which measures circulating microRNA-132 levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor.

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022, at 2:00 p.m. ET, and host investor meetings.

Marker Therapeutics, Inc. announced that Peter L. Hoang, Marker’s President and Chief Executive Officer, will participate in a panel discussion titled, “CAR-T and Beyond: What Are the Next Generation Cell Therapies?,” at the Cantor Fitzgerald Cell and Genetic Medicines Conference in New York on Thursday, September 15, 2022 at 9:20 a.m. ET.

H-CYTE, Inc., a medical biosciences company, announced that the Company completed the acquisition of Jantibody.

Axsome Therapeutics, Inc. announced that it has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an investigational treatment for Alzheimer’s disease agitation.

Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, will present initial data on their novel non-invasive saliva profiling assay for Sjögren’s Syndrome diagnosis and monitoring at the 15th International Symposium on Sjögren’s Syndrome in Rome, Italy on Friday Sept 9.

Valneva SE and VBI Vaccines Inc. announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine ], the only 3-antigen hepatitis B vaccine approved in Europe.

Teva Pharmaceutical Industries Ltd. announces the results of two studies1,2 presented at the Migraine Trust International Symposium in London, UK, which demonstrate the efficacy of AJOVY▼ in migraine patients who also experience depression or anxiety.

Genus, a leading global animal genetics company, announces its preliminary results for the year ended 30 June 2022.